FLT3 and acute myeloid leukemia: While pediatric studies are currently lacking, two upcoming pediatric trials will investigate the use of gilteritinib in FLT3-mutated AML in combination with chemotherapy in both the relapse and upfront settings (NCT04240002, NCT04293562).